Global and United States NSAIDs for Dysmenorrhea Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen are the NSAIDs specifically approved by the US Food and Drug Administration (FDA) for treatment of dysmenorrhea.

Market Analysis and Insights: Global and United States NSAIDs for Dysmenorrhea Market

This report focuses on global and United States NSAIDs for Dysmenorrhea market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global NSAIDs for Dysmenorrhea market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Ibuprofen accounting for % of the NSAIDs for Dysmenorrhea global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hospital was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.

In United States the NSAIDs for Dysmenorrhea market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period  2022-2028.

Global NSAIDs for Dysmenorrhea Scope and Market Size
NSAIDs for Dysmenorrhea market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global NSAIDs for Dysmenorrhea market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the NSAIDs for Dysmenorrhea market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    Ibuprofen
    Celecoxib
    Ketoprofen
    Others

Segment by Application
    Hospital
    Clinic
    Pharmacy
    Other

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
        Colombia
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    IOLCP
    Granules Biocause
    Strides Shasun
    BASF
    SI Group
    Hisoar
    Pfizer Inc
    Teva
    Mylan
    Apotex
    Lupin
    SANOFI-Aventis
    Boehringer-Ingelheim
    BEC Chemicals
    Shandong Xinhua Pharmaceutical
    Hengrui Medicine
    Hubei Biocause Heilen Pharmaceutical
    Zibo Xinhua-PERRIGO Pharmaceutical
    Zhejiang Jiuzhou
    Hubei Xunda

 1 Study Coverage
    1.1 NSAIDs for Dysmenorrhea Product Introduction
    1.2 Global NSAIDs for Dysmenorrhea Outlook 2017 VS 2022 VS 2028
        1.2.1 Global NSAIDs for Dysmenorrhea Sales in US$ Million for the Year 2017-2028
        1.2.2 Global NSAIDs for Dysmenorrhea Sales in Volume for the Year 2017-2028
    1.3 United States NSAIDs for Dysmenorrhea Outlook 2017 VS 2022 VS 2028
        1.3.1 United States NSAIDs for Dysmenorrhea Sales in US$ Million for the Year 2017-2028
        1.3.2 United States NSAIDs for Dysmenorrhea Sales in Volume for the Year 2017-2028
    1.4 NSAIDs for Dysmenorrhea Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.4.1 The Market Share of United States NSAIDs for Dysmenorrhea in Global, 2017 VS 2022 VS 2028
        1.4.2 The Growth Rate of NSAIDs for Dysmenorrhea Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.5 NSAIDs for Dysmenorrhea Market Dynamics
        1.5.1 NSAIDs for Dysmenorrhea Industry Trends
        1.5.2 NSAIDs for Dysmenorrhea Market Drivers
        1.5.3 NSAIDs for Dysmenorrhea Market Challenges
        1.5.4 NSAIDs for Dysmenorrhea Market Restraints
    1.6 Study Objectives
    1.7 Years Considered

 2 Market by Type
    2.1 NSAIDs for Dysmenorrhea Market Segment by Type
        2.1.1 Ibuprofen
        2.1.2 Celecoxib
        2.1.3 Ketoprofen
        2.1.4 Others
    2.2 Global NSAIDs for Dysmenorrhea Market Size by Type
        2.2.1 Global NSAIDs for Dysmenorrhea Sales in Value, by Type (2017, 2022 & 2028)
        2.2.2 Global NSAIDs for Dysmenorrhea Sales in Volume, by Type (2017, 2022 & 2028)
        2.2.3 Global NSAIDs for Dysmenorrhea Average Selling Price (ASP) by Type (2017, 2022 & 2028)
    2.3 United States NSAIDs for Dysmenorrhea Market Size by Type
        2.3.1 United States NSAIDs for Dysmenorrhea Sales in Value, by Type (2017, 2022 & 2028)
        2.3.2 United States NSAIDs for Dysmenorrhea Sales in Volume, by Type (2017, 2022 & 2028)
        2.3.3 United States NSAIDs for Dysmenorrhea Average Selling Price (ASP) by Type (2017, 2022 & 2028)

 3 Market by Application
    3.1 NSAIDs for Dysmenorrhea Market Segment by Application
        3.1.1 Hospital
        3.1.2 Clinic
        3.1.3 Pharmacy
        3.1.4 Other
    3.2 Global NSAIDs for Dysmenorrhea Market Size by Application
        3.2.1 Global NSAIDs for Dysmenorrhea Sales in Value, by Application (2017, 2022 & 2028)
        3.2.2 Global NSAIDs for Dysmenorrhea Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 Global NSAIDs for Dysmenorrhea Average Selling Price (ASP) by Application (2017, 2022 & 2028)
    3.3 United States NSAIDs for Dysmenorrhea Market Size by Application
        3.3.1 United States NSAIDs for Dysmenorrhea Sales in Value, by Application (2017, 2022 & 2028)
        3.3.2 United States NSAIDs for Dysmenorrhea Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 United States NSAIDs for Dysmenorrhea Average Selling Price (ASP) by Application (2017, 2022 & 2028)

 4 Global NSAIDs for Dysmenorrhea Competitor Landscape by Company
    4.1 Global NSAIDs for Dysmenorrhea Market Size by Company
        4.1.1 Top Global NSAIDs for Dysmenorrhea Manufacturers Ranked by Revenue (2021)
        4.1.2 Global NSAIDs for Dysmenorrhea Revenue by Manufacturer (2017-2022)
        4.1.3 Global NSAIDs for Dysmenorrhea Sales by Manufacturer (2017-2022)
        4.1.4 Global NSAIDs for Dysmenorrhea Price by Manufacturer (2017-2022)
    4.2 Global NSAIDs for Dysmenorrhea Concentration Ratio (CR)
        4.2.1 NSAIDs for Dysmenorrhea Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Manufacturers of NSAIDs for Dysmenorrhea in 2021
        4.2.3 Global NSAIDs for Dysmenorrhea Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global NSAIDs for Dysmenorrhea Manufacturing Base Distribution, Product Type
        4.3.1 Global NSAIDs for Dysmenorrhea Manufacturers, Headquarters and Distribution of Producing Region
        4.3.2 Manufacturers NSAIDs for Dysmenorrhea Product Type
        4.3.3 Date of International Manufacturers Enter into NSAIDs for Dysmenorrhea Market
    4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
    4.5 United States NSAIDs for Dysmenorrhea Market Size by Company
        4.5.1 Top NSAIDs for Dysmenorrhea Players in United States, Ranked by Revenue (2021)
        4.5.2 United States NSAIDs for Dysmenorrhea Revenue by Players (2020, 2021 & 2022)
        4.5.3 United States NSAIDs for Dysmenorrhea Sales by Players (2020, 2021 & 2022)

 5 Global NSAIDs for Dysmenorrhea Market Size by Region
    5.1 Global NSAIDs for Dysmenorrhea Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global NSAIDs for Dysmenorrhea Market Size in Volume by Region (2017-2028)
        5.2.1 Global NSAIDs for Dysmenorrhea Sales in Volume by Region: 2017-2022
        5.2.2 Global NSAIDs for Dysmenorrhea Sales in Volume Forecast by Region (2023-2028)
    5.3 Global NSAIDs for Dysmenorrhea Market Size in Value by Region (2017-2028)
        5.3.1 Global NSAIDs for Dysmenorrhea Sales in Value by Region: 2017-2022
        5.3.2 Global NSAIDs for Dysmenorrhea Sales in Value by Region: 2023-2028

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America NSAIDs for Dysmenorrhea Market Size YoY Growth 2017-2028
        6.1.2 North America NSAIDs for Dysmenorrhea Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 United States
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific NSAIDs for Dysmenorrhea Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific NSAIDs for Dysmenorrhea Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 China Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe NSAIDs for Dysmenorrhea Market Size YoY Growth 2017-2028
        6.3.2 Europe NSAIDs for Dysmenorrhea Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America NSAIDs for Dysmenorrhea Market Size YoY Growth 2017-2028
        6.4.2 Latin America NSAIDs for Dysmenorrhea Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
        6.4.6 Colombia
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa NSAIDs for Dysmenorrhea Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa NSAIDs for Dysmenorrhea Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 IOLCP
        7.1.1 IOLCP Corporation Information
        7.1.2 IOLCP Description and Business Overview
        7.1.3 IOLCP NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.1.4 IOLCP NSAIDs for Dysmenorrhea Products Offered
        7.1.5 IOLCP Recent Development
    7.2 Granules Biocause
        7.2.1 Granules Biocause Corporation Information
        7.2.2 Granules Biocause Description and Business Overview
        7.2.3 Granules Biocause NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.2.4 Granules Biocause NSAIDs for Dysmenorrhea Products Offered
        7.2.5 Granules Biocause Recent Development
    7.3 Strides Shasun
        7.3.1 Strides Shasun Corporation Information
        7.3.2 Strides Shasun Description and Business Overview
        7.3.3 Strides Shasun NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.3.4 Strides Shasun NSAIDs for Dysmenorrhea Products Offered
        7.3.5 Strides Shasun Recent Development
    7.4 BASF
        7.4.1 BASF Corporation Information
        7.4.2 BASF Description and Business Overview
        7.4.3 BASF NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.4.4 BASF NSAIDs for Dysmenorrhea Products Offered
        7.4.5 BASF Recent Development
    7.5 SI Group
        7.5.1 SI Group Corporation Information
        7.5.2 SI Group Description and Business Overview
        7.5.3 SI Group NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.5.4 SI Group NSAIDs for Dysmenorrhea Products Offered
        7.5.5 SI Group Recent Development
    7.6 Hisoar
        7.6.1 Hisoar Corporation Information
        7.6.2 Hisoar Description and Business Overview
        7.6.3 Hisoar NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.6.4 Hisoar NSAIDs for Dysmenorrhea Products Offered
        7.6.5 Hisoar Recent Development
    7.7 Pfizer Inc
        7.7.1 Pfizer Inc Corporation Information
        7.7.2 Pfizer Inc Description and Business Overview
        7.7.3 Pfizer Inc NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.7.4 Pfizer Inc NSAIDs for Dysmenorrhea Products Offered
        7.7.5 Pfizer Inc Recent Development
    7.8 Teva
        7.8.1 Teva Corporation Information
        7.8.2 Teva Description and Business Overview
        7.8.3 Teva NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.8.4 Teva NSAIDs for Dysmenorrhea Products Offered
        7.8.5 Teva Recent Development
    7.9 Mylan
        7.9.1 Mylan Corporation Information
        7.9.2 Mylan Description and Business Overview
        7.9.3 Mylan NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.9.4 Mylan NSAIDs for Dysmenorrhea Products Offered
        7.9.5 Mylan Recent Development
    7.10 Apotex
        7.10.1 Apotex Corporation Information
        7.10.2 Apotex Description and Business Overview
        7.10.3 Apotex NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.10.4 Apotex NSAIDs for Dysmenorrhea Products Offered
        7.10.5 Apotex Recent Development
    7.11 Lupin
        7.11.1 Lupin Corporation Information
        7.11.2 Lupin Description and Business Overview
        7.11.3 Lupin NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.11.4 Lupin NSAIDs for Dysmenorrhea Products Offered
        7.11.5 Lupin Recent Development
    7.12 SANOFI-Aventis
        7.12.1 SANOFI-Aventis Corporation Information
        7.12.2 SANOFI-Aventis Description and Business Overview
        7.12.3 SANOFI-Aventis NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.12.4 SANOFI-Aventis Products Offered
        7.12.5 SANOFI-Aventis Recent Development
    7.13 Boehringer-Ingelheim
        7.13.1 Boehringer-Ingelheim Corporation Information
        7.13.2 Boehringer-Ingelheim Description and Business Overview
        7.13.3 Boehringer-Ingelheim NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.13.4 Boehringer-Ingelheim Products Offered
        7.13.5 Boehringer-Ingelheim Recent Development
    7.14 BEC Chemicals
        7.14.1 BEC Chemicals Corporation Information
        7.14.2 BEC Chemicals Description and Business Overview
        7.14.3 BEC Chemicals NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.14.4 BEC Chemicals Products Offered
        7.14.5 BEC Chemicals Recent Development
    7.15 Shandong Xinhua Pharmaceutical
        7.15.1 Shandong Xinhua Pharmaceutical Corporation Information
        7.15.2 Shandong Xinhua Pharmaceutical Description and Business Overview
        7.15.3 Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.15.4 Shandong Xinhua Pharmaceutical Products Offered
        7.15.5 Shandong Xinhua Pharmaceutical Recent Development
    7.16 Hengrui Medicine
        7.16.1 Hengrui Medicine Corporation Information
        7.16.2 Hengrui Medicine Description and Business Overview
        7.16.3 Hengrui Medicine NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.16.4 Hengrui Medicine Products Offered
        7.16.5 Hengrui Medicine Recent Development
    7.17 Hubei Biocause Heilen Pharmaceutical
        7.17.1 Hubei Biocause Heilen Pharmaceutical Corporation Information
        7.17.2 Hubei Biocause Heilen Pharmaceutical Description and Business Overview
        7.17.3 Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.17.4 Hubei Biocause Heilen Pharmaceutical Products Offered
        7.17.5 Hubei Biocause Heilen Pharmaceutical Recent Development
    7.18 Zibo Xinhua-PERRIGO Pharmaceutical
        7.18.1 Zibo Xinhua-PERRIGO Pharmaceutical Corporation Information
        7.18.2 Zibo Xinhua-PERRIGO Pharmaceutical Description and Business Overview
        7.18.3 Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.18.4 Zibo Xinhua-PERRIGO Pharmaceutical Products Offered
        7.18.5 Zibo Xinhua-PERRIGO Pharmaceutical Recent Development
    7.19 Zhejiang Jiuzhou
        7.19.1 Zhejiang Jiuzhou Corporation Information
        7.19.2 Zhejiang Jiuzhou Description and Business Overview
        7.19.3 Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.19.4 Zhejiang Jiuzhou Products Offered
        7.19.5 Zhejiang Jiuzhou Recent Development
    7.20 Hubei Xunda
        7.20.1 Hubei Xunda Corporation Information
        7.20.2 Hubei Xunda Description and Business Overview
        7.20.3 Hubei Xunda NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2017-2022)
        7.20.4 Hubei Xunda Products Offered
        7.20.5 Hubei Xunda Recent Development

 8 Industry Chain and Sales Channels Analysis
    8.1 NSAIDs for Dysmenorrhea Industry Chain Analysis
    8.2 NSAIDs for Dysmenorrhea Key Raw Materials
        8.2.1 Key Raw Materials
        8.2.2 NSAIDs for Dysmenorrhea Distributors
    8.3 NSAIDs for Dysmenorrhea Production Mode & Process
    8.4 NSAIDs for Dysmenorrhea Sales and Marketing
        8.4.1 NSAIDs for Dysmenorrhea Sales Channels
        8.4.2 NSAIDs for Dysmenorrhea Distributors
    8.5 NSAIDs for Dysmenorrhea Customers

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. NSAIDs for Dysmenorrhea CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. NSAIDs for Dysmenorrhea Market Trends
    Table 3. NSAIDs for Dysmenorrhea Market Drivers
    Table 4. NSAIDs for Dysmenorrhea Market Challenges
    Table 5. NSAIDs for Dysmenorrhea Market Restraints
    Table 6. Global NSAIDs for Dysmenorrhea Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States NSAIDs for Dysmenorrhea Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global NSAIDs for Dysmenorrhea Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States NSAIDs for Dysmenorrhea Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top NSAIDs for Dysmenorrhea Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global NSAIDs for Dysmenorrhea Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global NSAIDs for Dysmenorrhea Revenue Share by Manufacturer, 2017-2022
    Table 13. Global NSAIDs for Dysmenorrhea Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global NSAIDs for Dysmenorrhea Sales Share by Manufacturer, 2017-2022
    Table 15. Global NSAIDs for Dysmenorrhea Price by Manufacturer (2017-2022) & (US$/Unit)
    Table 16. Global NSAIDs for Dysmenorrhea Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global NSAIDs for Dysmenorrhea by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NSAIDs for Dysmenorrhea as of 2021)
    Table 18. Top Players of NSAIDs for Dysmenorrhea in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers NSAIDs for Dysmenorrhea Product Type
    Table 20. Date of International Manufacturers Enter into NSAIDs for Dysmenorrhea Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top NSAIDs for Dysmenorrhea Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States NSAIDs for Dysmenorrhea Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States NSAIDs for Dysmenorrhea Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States NSAIDs for Dysmenorrhea Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States NSAIDs for Dysmenorrhea Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global NSAIDs for Dysmenorrhea Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global NSAIDs for Dysmenorrhea Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global NSAIDs for Dysmenorrhea Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global NSAIDs for Dysmenorrhea Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global NSAIDs for Dysmenorrhea Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America NSAIDs for Dysmenorrhea Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America NSAIDs for Dysmenorrhea Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific NSAIDs for Dysmenorrhea Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific NSAIDs for Dysmenorrhea Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe NSAIDs for Dysmenorrhea Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe NSAIDs for Dysmenorrhea Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America NSAIDs for Dysmenorrhea Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa NSAIDs for Dysmenorrhea Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa NSAIDs for Dysmenorrhea Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa NSAIDs for Dysmenorrhea Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. IOLCP Corporation Information
    Table 43. IOLCP Description and Business Overview
    Table 44. IOLCP NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 45. IOLCP NSAIDs for Dysmenorrhea Product
    Table 46. IOLCP Recent Development
    Table 47. Granules Biocause Corporation Information
    Table 48. Granules Biocause Description and Business Overview
    Table 49. Granules Biocause NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 50. Granules Biocause Product
    Table 51. Granules Biocause Recent Development
    Table 52. Strides Shasun Corporation Information
    Table 53. Strides Shasun Description and Business Overview
    Table 54. Strides Shasun NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 55. Strides Shasun Product
    Table 56. Strides Shasun Recent Development
    Table 57. BASF Corporation Information
    Table 58. BASF Description and Business Overview
    Table 59. BASF NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 60. BASF Product
    Table 61. BASF Recent Development
    Table 62. SI Group Corporation Information
    Table 63. SI Group Description and Business Overview
    Table 64. SI Group NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 65. SI Group Product
    Table 66. SI Group Recent Development
    Table 67. Hisoar Corporation Information
    Table 68. Hisoar Description and Business Overview
    Table 69. Hisoar NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 70. Hisoar Product
    Table 71. Hisoar Recent Development
    Table 72. Pfizer Inc Corporation Information
    Table 73. Pfizer Inc Description and Business Overview
    Table 74. Pfizer Inc NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 75. Pfizer Inc Product
    Table 76. Pfizer Inc Recent Development
    Table 77. Teva Corporation Information
    Table 78. Teva Description and Business Overview
    Table 79. Teva NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 80. Teva Product
    Table 81. Teva Recent Development
    Table 82. Mylan Corporation Information
    Table 83. Mylan Description and Business Overview
    Table 84. Mylan NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 85. Mylan Product
    Table 86. Mylan Recent Development
    Table 87. Apotex Corporation Information
    Table 88. Apotex Description and Business Overview
    Table 89. Apotex NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 90. Apotex Product
    Table 91. Apotex Recent Development
    Table 92. Lupin Corporation Information
    Table 93. Lupin Description and Business Overview
    Table 94. Lupin NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 95. Lupin Product
    Table 96. Lupin Recent Development
    Table 97. SANOFI-Aventis Corporation Information
    Table 98. SANOFI-Aventis Description and Business Overview
    Table 99. SANOFI-Aventis NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 100. SANOFI-Aventis Product
    Table 101. SANOFI-Aventis Recent Development
    Table 102. Boehringer-Ingelheim Corporation Information
    Table 103. Boehringer-Ingelheim Description and Business Overview
    Table 104. Boehringer-Ingelheim NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 105. Boehringer-Ingelheim Product
    Table 106. Boehringer-Ingelheim Recent Development
    Table 107. BEC Chemicals Corporation Information
    Table 108. BEC Chemicals Description and Business Overview
    Table 109. BEC Chemicals NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 110. BEC Chemicals Product
    Table 111. BEC Chemicals Recent Development
    Table 112. Shandong Xinhua Pharmaceutical Corporation Information
    Table 113. Shandong Xinhua Pharmaceutical Description and Business Overview
    Table 114. Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 115. Shandong Xinhua Pharmaceutical Product
    Table 116. Shandong Xinhua Pharmaceutical Recent Development
    Table 117. Hengrui Medicine Corporation Information
    Table 118. Hengrui Medicine Description and Business Overview
    Table 119. Hengrui Medicine NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 120. Hengrui Medicine Product
    Table 121. Hengrui Medicine Recent Development
    Table 122. Hubei Biocause Heilen Pharmaceutical Corporation Information
    Table 123. Hubei Biocause Heilen Pharmaceutical Description and Business Overview
    Table 124. Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 125. Hubei Biocause Heilen Pharmaceutical Product
    Table 126. Hubei Biocause Heilen Pharmaceutical Recent Development
    Table 127. Zibo Xinhua-PERRIGO Pharmaceutical Corporation Information
    Table 128. Zibo Xinhua-PERRIGO Pharmaceutical Description and Business Overview
    Table 129. Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 130. Zibo Xinhua-PERRIGO Pharmaceutical Product
    Table 131. Zibo Xinhua-PERRIGO Pharmaceutical Recent Development
    Table 132. Zhejiang Jiuzhou Corporation Information
    Table 133. Zhejiang Jiuzhou Description and Business Overview
    Table 134. Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 135. Zhejiang Jiuzhou Product
    Table 136. Zhejiang Jiuzhou Recent Development
    Table 137. Hubei Xunda Corporation Information
    Table 138. Hubei Xunda Description and Business Overview
    Table 139. Hubei Xunda NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 140. Hubei Xunda Product
    Table 141. Hubei Xunda Recent Development
    Table 142. Key Raw Materials Lists
    Table 143. Raw Materials Key Suppliers Lists
    Table 144. NSAIDs for Dysmenorrhea Customers List
    Table 145. NSAIDs for Dysmenorrhea Distributors List
    Table 146. Research Programs/Design for This Report
    Table 147. Key Data Information from Secondary Sources
    Table 148. Key Data Information from Primary Sources
List of Figures
    Figure 1. NSAIDs for Dysmenorrhea Product Picture
    Figure 2. Global NSAIDs for Dysmenorrhea Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global NSAIDs for Dysmenorrhea Market Size 2017-2028 (US$ Million)
    Figure 4. Global NSAIDs for Dysmenorrhea Sales 2017-2028 (K Units)
    Figure 5. United States NSAIDs for Dysmenorrhea Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States NSAIDs for Dysmenorrhea Market Size 2017-2028 (US$ Million)
    Figure 7. United States NSAIDs for Dysmenorrhea Sales 2017-2028 (K Units)
    Figure 8. United States NSAIDs for Dysmenorrhea Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States NSAIDs for Dysmenorrhea Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. NSAIDs for Dysmenorrhea Report Years Considered
    Figure 11. Product Picture of Ibuprofen
    Figure 12. Product Picture of Celecoxib
    Figure 13. Product Picture of Ketoprofen
    Figure 14. Product Picture of Others
    Figure 15. Global NSAIDs for Dysmenorrhea Market Share by Type in 2022 & 2028
    Figure 16. Global NSAIDs for Dysmenorrhea Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 17. Global NSAIDs for Dysmenorrhea Sales Market Share in Value by Type (2017-2028)
    Figure 18. Global NSAIDs for Dysmenorrhea Sales by Type (2017-2028) & (K Units)
    Figure 19. Global NSAIDs for Dysmenorrhea Sales Market Share in Volume by Type (2017-2028)
    Figure 20. Global NSAIDs for Dysmenorrhea Price by Type (2017-2028) & (US$/Unit)
    Figure 21. United States NSAIDs for Dysmenorrhea Market Share by Type in 2022 & 2028
    Figure 22. United States NSAIDs for Dysmenorrhea Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 23. United States NSAIDs for Dysmenorrhea Sales Market Share in Value by Type (2017-2028)
    Figure 24. United States NSAIDs for Dysmenorrhea Sales by Type (2017-2028) & (K Units)
    Figure 25. United States NSAIDs for Dysmenorrhea Sales Market Share in Volume by Type (2017-2028)
    Figure 26. United States NSAIDs for Dysmenorrhea Price by Type (2017-2028) & (US$/Unit)
    Figure 27. Product Picture of Hospital
    Figure 28. Product Picture of Clinic
    Figure 29. Product Picture of Pharmacy
    Figure 30. Product Picture of Other
    Figure 31. Global NSAIDs for Dysmenorrhea Market Share by Application in 2022 & 2028
    Figure 32. Global NSAIDs for Dysmenorrhea Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 33. Global NSAIDs for Dysmenorrhea Sales Market Share in Value by Application (2017-2028)
    Figure 34. Global NSAIDs for Dysmenorrhea Sales by Application (2017-2028) & (K Units)
    Figure 35. Global NSAIDs for Dysmenorrhea Sales Market Share in Volume by Application (2017-2028)
    Figure 36. Global NSAIDs for Dysmenorrhea Price by Application (2017-2028) & (US$/Unit)
    Figure 37. United States NSAIDs for Dysmenorrhea Market Share by Application in 2022 & 2028
    Figure 38. United States NSAIDs for Dysmenorrhea Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 39. United States NSAIDs for Dysmenorrhea Sales Market Share in Value by Application (2017-2028)
    Figure 40. United States NSAIDs for Dysmenorrhea Sales by Application (2017-2028) & (K Units)
    Figure 41. United States NSAIDs for Dysmenorrhea Sales Market Share in Volume by Application (2017-2028)
    Figure 42. United States NSAIDs for Dysmenorrhea Price by Application (2017-2028) & (US$/Unit)
    Figure 43. North America NSAIDs for Dysmenorrhea Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 44. North America NSAIDs for Dysmenorrhea Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 45. United States NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Canada NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Europe NSAIDs for Dysmenorrhea Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 48. Europe NSAIDs for Dysmenorrhea Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 49. Germany NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. France NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. U.K. NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Italy NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Russia NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Asia-Pacific NSAIDs for Dysmenorrhea Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 55. Asia-Pacific NSAIDs for Dysmenorrhea Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 56. China NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Japan NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. South Korea NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. India NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Australia NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. China Taiwan NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Indonesia NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Thailand NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Malaysia NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Latin America NSAIDs for Dysmenorrhea Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 66. Latin America NSAIDs for Dysmenorrhea Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 67. Mexico NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Brazil NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Argentina NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Colombia NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Middle East & Africa NSAIDs for Dysmenorrhea Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 72. Middle East & Africa NSAIDs for Dysmenorrhea Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 73. Turkey NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. Saudi Arabia NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. UAE NSAIDs for Dysmenorrhea Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 76. NSAIDs for Dysmenorrhea Value Chain
    Figure 77. NSAIDs for Dysmenorrhea Production Process
    Figure 78. Channels of Distribution
    Figure 79. Distributors Profiles
    Figure 80. Bottom-up and Top-down Approaches for This Report
    Figure 81. Data Triangulation
    Figure 82. Key Executives Interviewed

Diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen are the NSAIDs specifically approved by the US Food and Drug Administration (FDA) for treatment of dysmenorrhea.

Market Analysis and Insights: Global and United States NSAIDs for Dysmenorrhea Market

This report focuses on global and United States NSAIDs for Dysmenorrhea market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global NSAIDs for Dysmenorrhea market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Ibuprofen accounting for % of the NSAIDs for Dysmenorrhea global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hospital was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.

In United States the NSAIDs for Dysmenorrhea market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period  2022-2028.

Global NSAIDs for Dysmenorrhea Scope and Market Size
NSAIDs for Dysmenorrhea market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global NSAIDs for Dysmenorrhea market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the NSAIDs for Dysmenorrhea market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    Ibuprofen
    Celecoxib
    Ketoprofen
    Others

Segment by Application
    Hospital
    Clinic
    Pharmacy
    Other

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
        Colombia
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    IOLCP
    Granules Biocause
    Strides Shasun
    BASF
    SI Group
    Hisoar
    Pfizer Inc
    Teva
    Mylan
    Apotex
    Lupin
    SANOFI-Aventis
    Boehringer-Ingelheim
    BEC Chemicals
    Shandong Xinhua Pharmaceutical
    Hengrui Medicine
    Hubei Biocause Heilen Pharmaceutical
    Zibo Xinhua-PERRIGO Pharmaceutical
    Zhejiang Jiuzhou
    Hubei Xunda